G2B BioSolutions ApS: Financial statements 2022
CVR: 42437069
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
G2B BioSolutions ApS (CVR 42437069) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -171,184 and a net result of DKK -218,552. Equity in the 2022 report amounted to DKK -207,191. The company had 1 employee in the financial year.
- Gross Profit
- DKK -171,184
- Profit/Loss
- DKK -218,552
- Equity
- DKK -207,191
- Total Assets
- DKK 67,504
- Employees
- 1
Official annual report
Keep an eye on G2B BioSolutions ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
G2B BioSolutions ApS has published its interim report for the period June 3, 2021 – December 31, 2021.
As of May 4, 2022, Dayanand Jadhav Holding ApS is registered as an owner of G2B BioSolutions ApS with an ownership share of 100%.
About G2B BioSolutions ApS
G2B BioSolutions ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dayanand Suryabhan Jadhav. The company is owned by Dayanand Jadhav Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 44,817 and a net result of DKK 136,864 compared with DKK 370,740 the year before. Equity in the 2025 report amounted to DKK -1,213,372.